PYC Therapeutics (ASX:PYC) has reported encouraging long-term data from its ongoing Phase 1/2 clinical program for VP-001, an investigational treatment targeting Retinitis Pigmentosa type 11. …
Latest Video
New Stories
-
Biotron reports promising advances in Hepatitis B program as lead candidate shows strong antiviral activity
November 15, 2025 - - Australian Biotech -
Recce Pharmaceuticals pays tribute to founder and scientific pioneer Dr Graham Melrose
November 15, 2025 - -
PYC reports sustained vision gains in RP11 clinical trial
November 15, 2025 - - Australian Biotech -
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
Prospection says data access and leadership are critical to unlock AI’s potential in healthcare
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments
November 14, 2025 - - Latest News